What do we really know about the safety and efficacy of melatonin for sleep disorders?

References

• Bernard C. Introduction à l’étude de la médecine expérimentale. Paris: J.-B. Baillière; 1865.
   Google Scholar
• Weaver DR. Reproductive safety of melatonin: a “wonder drug” to wonder about. J Biol Rhythms. 1997;12(6):682–689.
   PubMed Web of Science ®Google Scholar
• Sack RL, Lewy AJ, Hughes RJ. Use of melatonin for sleep and circadian rhythm disorders. Ann Med. 1998;30(1):115–121.
   PubMed Web of Science ®Google Scholar
• Rumbold AR, Sevoyan A, Oswald TK, et al. Impact of male factor infertility on offspring health and development. Fertil Steril. 2019;111(6):1047–1053.
   PubMed Web of Science ®Google Scholar
• Erland LA, Saxena PK. Melatonin natural health products and supplements: Presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–281.
   PubMed Web of Science ®Google Scholar
• Williamson BL, Tomlinson AJ, Mishra PK, et al. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. Chem Res Toxicol. 1998;11(3):234–240.
   PubMed Web of Science ®Google Scholar
• Grigg-Damberger MM, Ianakieva D. Poor quality control of over-the-counter melatonin: what they say is often not what you get. J Clin Sleep Med. 2017;13(2):163–165.
   PubMed Web of Science ®Google Scholar
• Kimland EE, Bardage C, Collin J, et al. Pediatric use of prescribed melatonin in Sweden 2006–2017: a register based study. Eur Child Adolesc Psychiatry. 2021;30(9):1339–1350.
   PubMed Web of Science ®Google Scholar
• Boafo A, Greenham S, Sullivan M, et al. Medications for sleep disturbance in children and adolescents with depression: a survey of Canadian child and adolescent psychiatrists. Child Adolesc Psychiatry Ment Health. 2020;14:10.
   PubMed Web of Science ®Google Scholar
• Nielsen ES, Rasmussen L, Hellfritzsch M, et al. Trends in off-label prescribing of sedatives, hypnotics and antidepressants among children and adolescents - a Danish, nationwide register-based study. Basic Clin Pharmacol Toxicol. 2017;120(4):360–367.
   PubMed Web of Science ®Google Scholar
• Brauner JV, Johansen LM, Roesbjerg T, et al. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol. 2016;36(5):500–507.
   PubMed Web of Science ®Google Scholar
• Furster C, Hallerback MU. The use of melatonin in Swedish children and adolescents-a register-based study according to age, gender, and medication of ADHD. Eur J Clin Pharmacol. 2015;71(7):877–881.
   PubMed Web of Science ®Google Scholar
• Nielsen E, Hellfritzsch M, Sørensen M, et al. Off-label prescribing of psychotropic drugs in a Danish child and adolescent psychiatric outpatient clinic. Eur Child Adolesc Psychiatry. 2016;25(1):25–27.
   PubMed Web of Science ®Google Scholar
• Efron D, Danchin MH, Cranswick NE, et al. Medication prescribed by Australian paediatricians: psychotropics predominate. J Paediatr Child Health. 2017;53(10):957–962.
   PubMed Web of Science ®Google Scholar
• Hartz I, Handal M, Tverdal A, et al. Paediatric off-label use of melatonin-a register linkage study between the norwegian prescription database and patient register. Basic Clin Pharmacol Toxicol. 2015;117(4):267–273.
   PubMed Web of Science ®Google Scholar
• Heussler H, Chan P, Price AM, et al. Pharmacological and non-pharmacological management of sleep disturbance in children: an Australian Paediatric Research Network survey. Sleep Med. 2013;14(2):189–194.
   PubMed Web of Science ®Google Scholar
• Fourtillan JB, Gobin P, Faye B, et al. A highly sensitive assay of melatonin at the femotogram level in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol Mass Spectrom. 1994;23(8):499–509.
   PubMedGoogle Scholar
• Fourtillan JB, Brisson AM, Fourtillan M, et al. Melatonin secretion occurs at a constant rate in both young and older men and women. Am J Physiol Endocrinol Metab. 2001;280(1):E11–22.
   PubMed Web of Science ®Google Scholar
• Sletten TL, Vincenzi S, Redman JR, et al. Timing of sleep and its relationship with the endogenous melatonin rhythm. Front Neurol. 2010;1:137.
   PubMedGoogle Scholar
• Iguchi H, Kato KI, Ibayashi H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab. 1982;54(5):1025–1027.
   PubMed Web of Science ®Google Scholar
• Fellenberg AJ, Phillipou G, Seamark RF. Measurement of urinary production rates of melatonin as an index of human pineal function. Endocr Res Commun. 1980;7(3):167–175.
   PubMed Web of Science ®Google Scholar
• Fourtillan JB, Brisson AM, Gobin P, et al. Bioavailability of melatonin in humans after day-time administration of D7 melatonin. Biopharm Drug Dispos. 2000;21(1):15–22.
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Wehr TA, Goodwin FK, et al. Light suppresses melatonin secretion in humans. Science. 1980;210(4475):1267–1269.
   PubMed Web of Science ®Google Scholar
• Wehr TA, Moul DE, Barbato G, et al. Conservation of photoperiod-responsive mechanisms in humans. Am J Physiol. 1993;265(4):R846–R857.
   PubMed Web of Science ®Google Scholar
• Stothard ER, McHill AW, Depner CM, et al. Circadian entrainment to the natural light-dark cycle across seasons and the weekend. Curr Biol. 2017;27(4):508–513.
   PubMed Web of Science ®Google Scholar
• Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. Br J Pharmacol. 2018;175(16):3263–3280.
   PubMed Web of Science ®Google Scholar
• Kennaway DJ, Gilmore TA, Dunstan EA. Pinealectomy delays puberty in ewe lambs. J Reprod Fertil. 1985;74(1):119–125.
   PubMedGoogle Scholar
• Ebihara S, Marks T, Hudson DJ, et al. Genetic control of melatonin synthesis in the pineal gland of the mouse. Science. 1986;231(4737):491–493.
   PubMed Web of Science ®Google Scholar
• Kennaway DJ. Melatonin research in mice: a review. Chronobiol Int. 2019;36(9):1167–1183.
   PubMed Web of Science ®Google Scholar
• Slawik H, Stoffel M, Riedl L, et al. Prospective study on salivary evening melatonin and sleep before and after pinealectomy in humans. J Biol Rhythms. 2016;31(1):82–93.
   PubMed Web of Science ®Google Scholar
• Keijzer H, Smits MG, Peeters T, et al. Evaluation of salivary melatonin measurements for Dim Light Melatonin Onset calculations in patients with possible sleep–wake rhythm disorders. Clin Chim Acta. 2011;412(17-18):1616–1620.
   PubMed Web of Science ®Google Scholar
• Rahman SA, Marcu S, Kayumov L, et al. Altered sleep architecture and higher incidence of subsyndromal depression in low endogenous melatonin secretors. Eur Arch Psychiatry Clin Neurosci. 2010;260(4):327–335.
   PubMed Web of Science ®Google Scholar
• Scheer FA, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. Sleep. 2012;35(10):1395–1402.
   PubMed Web of Science ®Google Scholar
• Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab. 1991;73(6):1276–1280.
   PubMed Web of Science ®Google Scholar
• Cipolla-Neto J, do Amaral FG. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev. 2018;39(6):990–1028.
   PubMed Web of Science ®Google Scholar
• Dollins AB, Zhdanova IV, Wurtman RJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A. 1994;91(5):1824–1828.
   PubMed Web of Science ®Google Scholar
• Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep. 1997;20(2):124–131.
   PubMed Web of Science ®Google Scholar
• Reid K, Van den Heuvel C, Dawson D. Day-time melatonin administration: effects on core temperature and sleep onset latency. J Sleep Res. 1996;5(3):150–154.
   PubMed Web of Science ®Google Scholar
• Lushington K, Pollard K, Lack L, et al. Daytime melatonin administration in elderly good and poor sleepers: effects on core body temperature and sleep latency. Sleep. 1997;20(12):1135–1144.
   PubMed Web of Science ®Google Scholar
• Gilbert SS, Heuvel CJ, Dawson D. Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures. J Physiol. 1999;514(3):905–914.
   PubMed Web of Science ®Google Scholar
• Harris AS, Burgess HJ, Dawson D. The effects of day-time exogenous melatonin administration on cardiac autonomic activity. J Pineal Res. 2001;31(3):199–205.
   PubMed Web of Science ®Google Scholar
• Holmes AL, Gilbert SS, Dawson D. Melatonin and zopiclone: the relationship between sleep propensity and body temperature. Sleep. 2002;25(3):301–306.
   PubMed Web of Science ®Google Scholar
• James SP, Mendelson WB, Sack DA, et al. The effect of melatonin on normal sleep. Neuropsychopharmacology. 1987;1(1):41–44.
   PubMed Web of Science ®Google Scholar
• Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy Middle-aged subjects. Psychopharmacology (Berl). 1996;126(2):179–181.
   PubMed Web of Science ®Google Scholar
• Zhdanova IV, Wurtman RJ, Morabito C, et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19(5):423–431.
   PubMed Web of Science ®Google Scholar
• Cajochen C, Krauchi K, Danilenko KV, et al. Evening administration of melatonin and bright light: interactions on the EEG during sleep and wakefulness. J Sleep Res. 1998;7(3):145–157.
   PubMed Web of Science ®Google Scholar
• Stone BM, Turner C, Mills SL, et al. Hypnotic activity of melatonin. Sleep. 2000;23(5):663–669.
   PubMed Web of Science ®Google Scholar
• Pires ML, A A, Pinto L, et al. Acute effects of low doses of melatonin on the sleep of young healthy subjects. J Pineal Res. 2001;31(4):326–332.
   PubMed Web of Science ®Google Scholar
• Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86(10):4727–4730.
   PubMed Web of Science ®Google Scholar
• Baskett JJ, Broad JB, Wood PC, et al. Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing. 2003;32(2):164–170.
   PubMed Web of Science ®Google Scholar
• Xiv DJ. On the temperature of man. Philos Trans R Soc Lond. 1845;135:319–333.
   Google Scholar
• Cagnacci A, Elliott JA, Ss Y. Melatonin: a major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab. 1992;75:447–452.
   PubMed Web of Science ®Google Scholar
• Dawson D, Gibbon S, Singh P. The hypothermic effect of melatonin on core body temperature: is more better? J Pineal Res. 1996;20(4):192–197.
   PubMed Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Wirz Justice A. A relationship between heat loss and sleepiness: effects of postural change and melatonin administration. J Appl Physiol (1985). 1997;83(1):134–139.
   PubMed Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Werth E, et al. Functional link between distal vasodilation and sleep-onset latency? Am J Physiol Regul Integr Comp Physiol. 2000;278(3):R741–R748.
   PubMed Web of Science ®Google Scholar
• Cook JS, Sauder CL, Ray CA. Melatonin differentially affects vascular blood flow in humans. Am J Physiol Heart Circ Physiol. 2011;300(2):H670–4.
   PubMed Web of Science ®Google Scholar
• Kräuchi K. The human sleep-wake cycle reconsidered from a thermoregulatory point of view. Physiol Behav. 2007;90(2–3):236–245.
   PubMed Web of Science ®Google Scholar
• Kräuchi K, Cajochen C, Pache M, et al. Thermoregulatory effects of melatonin in relation to sleepiness. Chronobiol Int. 2006;23(1–2):475–484.
   PubMed Web of Science ®Google Scholar
• Deacon S, Arendt J. Melatonin-induced temperature suppression and its acute phase- shifting effects correlate in a dose-dependent manner in humans. Brain Res. 1995;688(1–2):77–85.
   PubMed Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Danilenko KV, et al. The hypothermic effect of late evening melatonin does not block the phase delay induced by concurrent bright light in human subjects. Neurosci Lett. 1997;232(1):57–61.
   PubMed Web of Science ®Google Scholar
• Tamarkin L, Westrom WK, Hamill AI, et al. Effect of melatonin on the reproductive systems of male and female Syrian hamsters: a diurnal rhythm in sensitivity to melatonin. Endocrinology. 1976;99(6):1534–1541.
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Ahmed S, Jackson JM, et al. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9(5):380–392.
   PubMed Web of Science ®Google Scholar
• Burgess HJ, Revell VL, Molina TA, et al. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab. 2010;95(7):3325–3331.
   PubMed Web of Science ®Google Scholar
• Saxvig IW, Wilhelmsen-Langeland A, Pallesen S, et al. A randomized controlled trial with bright light and melatonin for delayed sleep phase disorder: effects on subjective and objective sleep. Chronobiol Int. 2014;31(1):72–86.
   PubMed Web of Science ®Google Scholar
• Keijzer H, Smits MG, Duffy JF, et al. Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders. Sleep Med Rev. 2014;18(4):333–339.
   PubMed Web of Science ®Google Scholar
• Redman J, Armstrong S, Ng KT. Free-running activity rhythms in the rat: entrainment by melatonin. Science. 1983;219(4588):1089–1091.
   PubMed Web of Science ®Google Scholar
• Malkani RG, Abbott SM, Reid KJ, et al. Diagnostic and treatment challenges of sighted non-24-hour sleep-wake disorder. J Clin Sleep Med. 2018;14(4):603–613.
   PubMed Web of Science ®Google Scholar
• Hack LM, Lockley SW, Arendt J, et al. The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. J Biol Rhythms. 2003;18(5):420–429.
   PubMed Web of Science ®Google Scholar
• Mahle CD, Goggins GD, Agarwal P, et al. Melatonin modulates vascular smooth muscle tone. J Biol Rhythms. 1997;12(6):690–696.
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhang H, Jin C, et al. Melatonin mediates vasodilation through both direct and indirect activation of BKCa channels. J Mol Endocrinol. 2017;59(3):219–233.
   PubMed Web of Science ®Google Scholar
• Xu ZX, Wu Y, Zhang YY, et al. Melatonin activates BKCa channels in cerebral artery myocytes via both direct and MT receptor/PKC-mediated pathway. Eur J Pharmacol. 2019;842:177–188.
   PubMed Web of Science ®Google Scholar
• Chucharoen P, Chetsawang B, Srikiatkhachorn A, et al. Melatonin receptor expression in rat cerebral artery. Neurosci Lett. 2003;341(3):259–261.
   PubMed Web of Science ®Google Scholar
• Ekmekcioglu C, Thalhammer T, Humpeler S, et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res. 2003;35(1):40–44.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Arangino S, Angiolucci M, et al. Potentially beneficial cardiovascular effects of melatonin administration in women. J Pineal Res. 1997;22(1):16–19.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Arangino S, Angiolucci M, et al. Influences of melatonin administration on the circulation of women. Am J Physiol. 1998;274(2):R335–8.
   PubMedGoogle Scholar
• Arangino S, Cagnacci A, Angiolucci M, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol. 1999;83(9):1417–1419.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Arangino S, Angiolucci M, et al. Different circulatory response to melatonin in postmenopausal women without and with hormone replacement therapy. J Pineal Res. 2000;29(3):152–158.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Arangino S, Angiolucci M, et al. Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. Clin Endocrinol (Oxf). 2001;54(2):261–266.
   PubMed Web of Science ®Google Scholar
• Nishiyama K, Yasue H, Moriyama Y, et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am Heart J. 2001;141(5):E9.
   PubMedGoogle Scholar
• Ray CA. Melatonin attenuates the sympathetic nerve responses to orthostatic stress in humans. J Physiol. 2003;551(3):1043–1048.
   PubMed Web of Science ®Google Scholar
• Yildiz M, Sahin B, Sahin A. Acute effects of oral melatonin administration on arterial distensibility, as determined by carotid-femoral pulse wave velocity, in healthy young men. Exp Clin Cardiol. 2006;11(4):311–313.
   PubMedGoogle Scholar
• Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab. 1977;45(4):768–774.
   PubMed Web of Science ®Google Scholar
• Wright J, Aldhous M, Franey C, et al. The effects of exogenous melatonin on endocrine function in man. Clin Endocrinol (Oxf). 1986;24(4):375–382.
   PubMed Web of Science ®Google Scholar
• Nickelsen T, Demisch L, Demisch K, et al. Influence of subchronic intake of melatonin at various times of the day on fatigue and hormonal levels: a placebo-controlled, double-blind trial. J Pineal Res. 1989;6(4):325–334.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Elliott JA, Yen SS. Amplification of pulsatile LH secretion by exogenous melatonin in women. J Clin Endocrinol Metab. 1991;73(1):210–212.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Soldani R, Yen SS. Exogenous melatonin enhances luteinizing hormone levels of women in the follicular but not in the luteal menstrual phase. Fertil Steril. 1995;63(5):996–999.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Paoletti AM, Soldani R, et al. Melatonin enhances the luteinizing hormone and follicle- stimulating hormone responses to gonadotropin-releasing hormone in the follicular, but not in the luteal, menstrual phase. J Clin Endocrinol Metab. 1995;80:1095–1099.
   PubMed Web of Science ®Google Scholar
• Luboshitzky R, Shen-Orr Z, Shochat T, et al. Melatonin administered in the afternoon decreases next-day luteinizing hormone levels in men - Lack of antagonism by flumazenil. JMN. 1999;12(1):75–80.
   Web of Science ®Google Scholar
• Luboshitzky R, Levi M, Shen OZ, et al. Long-term melatonin administration does not alter pituitary-gonadal hormone secretion in normal men. Hum Reprod. 2000;15(1):60–65.
   PubMed Web of Science ®Google Scholar
• Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab. 1992;74(1):108–117.
   PubMed Web of Science ®Google Scholar
• Kostoglou-Athanassiou I, Treacher DF, Wheeler MJ, et al. Melatonin administration and pituitary hormone secretion. Clin Endocrinol (Oxf). 1998;48(1):31–37.
   PubMed Web of Science ®Google Scholar
• Okatani Y, Sagara Y. Role of melatonin in nocturnal prolactin secretion in women with normoprolactinemia and mild hyperprolactinemia. Am J Obstet Gynecol. 1993;168(3):854–861.
   PubMed Web of Science ®Google Scholar
• Webley GE, Lenton EA. The temporal relationship between melatonin and prolactin in women. Fertil Steril. 1987;48(2):218–222.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Revelli A, Guidetti D, et al. Evening administration of melatonin enhances the pulsatile secretion of prolactin but not of LH and TSH in normally cycling women. Clin Endocrinol. 1993;39(2):185–191.
   PubMed Web of Science ®Google Scholar
• Forsling ML, Wheeler MJ, Williams AJ. The effect of melatonin administration on pituitary hormone secretion in man. Clin Endocrinol (Oxf). 1999;51(5):637–642.
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Iwatani N, Tomoda A, et al. Effects of exogenous melatonin on pituitary hormones in humans. Clin Physiol. 2001;21(3):292–299.
   PubMedGoogle Scholar
• Rajaratnam SM, Dijk DJ, Middleton B, et al. Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. J Clin Endocrinol Metab. 2003;88(9):4303–4309.
   PubMed Web of Science ®Google Scholar
• Yie SM, Niles LP, YoungLai EV. Melatonin receptors on human granulosa cell membranes. J Clin Endocrinol Metab. 1995;80(5):1747–1749.
   PubMed Web of Science ®Google Scholar
• Niles LP, Wang J, Shen L, et al. Melatonin receptor mRNA expression in human granulosa cells. Mol Cell Endocrinol. 1999;156(1–2):107–110.
   PubMed Web of Science ®Google Scholar
• Webley GE, Luck MR. Melatonin directly stimulates the secretion of progesterone by human and bovine granulosa cells in vitro. J Reprod Fertil. 1986;78(2):711–717.
   PubMedGoogle Scholar
• Brzezinski A, Fibich T, Cohen M, et al. Effects of melatonin on progesterone production by human granulosa lutein cells in culture. Fertil Steril. 1992;58(3):526–529.
   PubMed Web of Science ®Google Scholar
• Woo MM, Tai CJ, Kang SK, et al. Direct action of melatonin in human granulosa-luteal cells. J Clin Endocrinol Metab. 2001;86(10):4789–4797.
   PubMed Web of Science ®Google Scholar
• Scarinci E, Tropea A, Notaristefano G, et al. “Hormone of darkness” and human reproductive process: direct regulatory role of melatonin in human corpus luteum. J Endocrinol Invest. 2019;42(10):1191–1197.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Liu WJ, Wu CJ, et al. Melatonin suppresses apoptosis and stimulates progesterone production by bovine granulosa cells via its receptors (MT1 and MT2). Theriogenology. 2012;78(7):1517–1526.
   PubMed Web of Science ®Google Scholar
• Tamura H, Nakamura Y, Korkmaz A, et al. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril. 2009;92(1):328–343.
   PubMed Web of Science ®Google Scholar
• Taketani T, Tamura H, Takasaki A, et al. Protective role of melatonin in progesterone production by human luteal cells. J Pineal Res. 2011;51(2):207–213.
   PubMed Web of Science ®Google Scholar
• Fernando S, Wallace EM, Vollenhoven B, et al. Melatonin in assisted reproductive technology: a pilot double-blind randomized placebo-controlled clinical trial. Front Endocrinol. 2018;9:545.
   PubMed Web of Science ®Google Scholar
• Jahnke G, Marr M, Myers C, et al. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci. 1999;50(2):271–279.
   PubMed Web of Science ®Google Scholar
• Fernandez B, Diaz E, Colmenero MD, et al. Maternal pineal gland participates in prepubertal rats’ ovarian oocyte development. Anat Rec. 1995;243(4):461–465.
   PubMedGoogle Scholar
• Colmenero MD, Diaz B, Miguel JL, et al. Melatonin administration during pregnancy retards sexual maturation of female offspring in the rat. J Pineal Res. 1991;11(1):23–27.
   PubMed Web of Science ®Google Scholar
• Diaz Lopez B, Colmenero Urquijo MD, Diaz Rodriguez ME, et al. Effect of pinealectomy and melatonin treatment during pregnancy on the sexual development of the female and male rat offspring. Eur J Endocrinol. 1995;132(6):765–770.
   PubMed Web of Science ®Google Scholar
• Diaz RE, Debeljuk L, Esquifino A, et al. Prenatal melatonin influences developmental changes of tachykinins in response to estradiol benzoate. Peptides. 1999;20(1):71–80.
   PubMed Web of Science ®Google Scholar
• Dı́az E, Castrillón P, Esquifino A, et al. Effect of prenatal melatonin on the gonadotropin and prolactin response to the feedback effect of testosterone in male offspring. J Steroid Biochem Mol Biol. 2000;72(1–2):61–69.
   PubMed Web of Science ®Google Scholar
• Okatani Y, Wakatsuki A, Otukonyong EE, et al. Effect of prenatal melatonin exposure on gonadotropins and prolactin secretion in male and female rat pups. Eur J Pharmacol. 2001;424(3):229–235.
   PubMed Web of Science ®Google Scholar
• González-Candia A, Veliz M, Araya C, et al. Potential adverse effects of antenatal melatonin as a treatment for intrauterine growth restriction: findings in pregnant sheep. Am J Obstet Gynecol. 2016;215(2):245.e1–245.e7.
   Web of Science ®Google Scholar
• Marseglia L, D’Angelo G, Manti S, et al. Potential utility of melatonin in preeclampsia, intrauterine fetal growth retardation, and perinatal asphyxia. Reprod Sci. 2016;23(8):970–977.
   PubMed Web of Science ®Google Scholar
• Hu KL, Ye XH, Wang SW, et al. Melatonin application in assisted reproductive technology: a systematic review and Meta-analysis of randomized trials. Front Endocrinol (Lausanne). 2020;11:160.
   PubMed Web of Science ®Google Scholar
• Tagliaferri V, Romualdi D, Scarinci E, et al. Melatonin treatment may be able to restore menstrual cyclicity in women with PCOS: a pilot study. Reprod Sci. 2018;25(2):269–275.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu H, Sun J, et al. Effect of melatonin on the peripheral T lymphocyte cell cycle and levels of reactive oxygen species in patients with premature ovarian failure. Exp Ther Med. 2016;12(6):3589–3594.
   PubMed Web of Science ®Google Scholar
• Hobson SR, Gurusinghe S, Lim R, et al. Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. J Pineal Res. 2018;65(3):e12508.
   PubMed Web of Science ®Google Scholar
• Luboshitzky R, Shen-Orr Z, Nave R, et al. Melatonin administration alters semen quality in healthy men. J Androl. 2002;23(4):572–578.
   PubMedGoogle Scholar
• Lerchl A. Melatonin administration alters semen quality in normal men. J Androl. 2004;25(2):185–186.
   PubMedGoogle Scholar
• Tamura H, Jozaki M, Tanabe M, et al. Importance of melatonin in assisted reproductive technology and ovarian aging. IJMS. 2020;21(3):1135.
   Web of Science ®Google Scholar
• Cagnacci A, Arangino S, Renzi A, et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol. 2001;54(3):339–346.
   PubMed Web of Science ®Google Scholar
• Rubio-Sastre P, Scheer FA, Gomez-Abellan P, et al. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014;37(10):1715–1719.
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Zorin M, Wainstein J, et al. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 2011;4:307–313.
   PubMedGoogle Scholar
• Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–88.
   PubMed Web of Science ®Google Scholar
• Soranzo N, Sanna S, Wheeler E, et al. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010;59(12):3229–3239.
   PubMed Web of Science ®Google Scholar
• Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77–81.
   PubMed Web of Science ®Google Scholar
• Bonnefond A, Clement N, Fawcett K, et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet. 2012;44(3):297–301.
   PubMed Web of Science ®Google Scholar
• Dashti HS, Follis JL, Smith CE, et al. Gene-environment interactions of circadian-related genes for cardiometabolic traits. Dia Care. 2015;38(8):1456–1466.
   PubMed Web of Science ®Google Scholar
• Garaulet M, Gómez-Abellán P, Rubio-Sastre P, et al. Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans. Metabolism. 2015;64(12):1650–1657.
   PubMed Web of Science ®Google Scholar
• Tuomi T, Nagorny CLF, Singh P, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016;23(6):1067–1077.
   PubMed Web of Science ®Google Scholar
• Lopez-Minguez J, Saxena R, Bandín C, et al. Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: a randomized, cross-over study. Clin Nutr. 2018;37(4):1133–1140.
   PubMed Web of Science ®Google Scholar
• Amstrup AK, Sikjaer T, Pedersen SB, et al. Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2016;84(3):342–347.
   PubMed Web of Science ®Google Scholar
• Szewczyk-Golec K, Rajewski P, Gackowski M, et al. Melatonin supplementation lowers oxidative stress and regulates adipokines in obese patients on a calorie-restricted diet. Oxid Med Cell Longev. 2017; 2017:8494107.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Malmusi S, Zanni A, et al. Acute modifications in the levels of daytime melatonin do not influence leptin in postmenopausal women. J Pineal Res. 2002;33(1):57–60.
   PubMed Web of Science ®Google Scholar
• Deacon S, English J, Arendt J. Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans. Neurosci Lett. 1994;178(1):32–34.
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Ahmed S, Sack RL. Phase shifting the human circadian clock using melatonin. Behav Brain Res. 1996;73(1–2):131–134.
   PubMed Web of Science ®Google Scholar
• DTBteam. Melatonin for jet lag. Drug Ther Bull. 2020;58(2):21–24.
   PubMedGoogle Scholar
• Burke TM, Markwald RR, Chinoy ED, et al. Combination of light and melatonin time cues for phase advancing the human circadian clock. Sleep. 2013;36(11):1617–1624.
   PubMed Web of Science ®Google Scholar
• Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol. 2000;49(5):423–427.
   PubMed Web of Science ®Google Scholar
• von Bahr C, Ursing C, Yasui N, et al. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects– an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol. 2000;56(2):123–127.
   PubMed Web of Science ®Google Scholar
• Ursing C, Wikner J, Brismar K, et al. Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450(CYP)1A2. J Endocrinol Invest. 2003;26(5):403–406.
   PubMed Web of Science ®Google Scholar
• Hilli J, Korhonen T, Turpeinen M, et al. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C > a polymorphism. J Clin Pharmacol. 2008;48(8):986–994.
   PubMed Web of Science ®Google Scholar
• Foster BC, Cvijovic K, Boon HS, et al. Melatonin interaction resulting in severe sedation. J Pharm Pharm Sci. 2015;18(2):124–131.
   PubMed Web of Science ®Google Scholar
• Papagiannidou E, Skene DJ, Ioannides C. Potential drug interactions with melatonin. Physiol Behav. 2014;131:17–24.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhou SF. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066–4218.
   PubMed Web of Science ®Google Scholar
• Gurusamy U, Shewade DG. Chapter 46 - pharmacogenomics in India. In: Padmanabhan S, editor. Handbook of pharmacogenomics and stratified medicine. San Diego (CA): Academic Press; 2014. p. 1037–1059.
   Google Scholar
• Huuhka K, Riutta A, Haataja R, et al. The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: a randomized, double-blind, placebo-controlled study. Methods Find Exp Clin Pharmacol. 2006;28(7):447–450.
   PubMedGoogle Scholar
• Wang C, Huo X, Tian X, et al. Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model. Br J Pharmacol. 2016;173(22):3261–3275.
   PubMed Web of Science ®Google Scholar
• Jiang W, Tian X, Wang Y, et al. The natural anthraquinones from rheum palmatum induced the metabolic disorder of melatonin by inhibiting human CYP and SULT enzymes. Toxicol Lett. 2016;262:27–38.
   PubMed Web of Science ®Google Scholar
• Jana S, Rastogi H. Effects of caffeic acid and quercetin on in vitro permeability, metabolism and in vivo pharmacokinetics of melatonin in rats: potential for herb-drug interaction. Eur J Drug Metab Pharmacokinet. 2017;42(5):781–791.
   PubMed Web of Science ®Google Scholar
• McArthur AJ, Budden SS. Sleep dysfunction in rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol. 2008;40(3):186–192.
   Google Scholar
• Smits MG, Nagtegaal EE, van der HJ, et al. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child Neurol. 2001;16(2):86–92.
   PubMed Web of Science ®Google Scholar
• Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23(10):2597–2605.
   PubMed Web of Science ®Google Scholar
• Van Der Heijden KB, Smits MG, Van Someren EJW, et al. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46(2):233–241.
   PubMed Web of Science ®Google Scholar
• Hoebert M, van der Heijden KB, van Geijlswijk IM, et al. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res. 2009;47(1):1–7.
   PubMed Web of Science ®Google Scholar
• Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8(1):18.
   PubMed Web of Science ®Google Scholar
• Zwart TC, Smits MG, Egberts TCG, et al. Long-term melatonin therapy for adolescents and young adults with chronic sleep onset insomnia and late melatonin onset: Evaluation of sleep quality, chronotype, and lifestyle factors compared to age-related randomly selected population cohorts. Healthcare. 2018;6(1):23.
   Web of Science ®Google Scholar
• Malow BA, Findling RL, Schroder CM, et al. Sleep, growth, and puberty after two years of prolonged-release melatonin in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2021;60(2):252–261.
   PubMed Web of Science ®Google Scholar
• van Geijlswijk IM, Mol RH, Egberts TC, et al. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. Psychopharmacology (Berl). 2011;216(1):111–120.
   PubMed Web of Science ®Google Scholar
• Carr R, Wasdell MB, Hamilton D, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007;43(4):351–359.
   PubMed Web of Science ®Google Scholar
• Boafo A, Greenham S, Alenezi S, et al. Could long-term administration of melatonin to prepubertal children affect timing of puberty? A clinician’s perspective. Nat Sci Sleep. 2019;11:1–10.
   PubMed Web of Science ®Google Scholar
• Besag FMC, Vasey MJ, Lao KSJ, et al. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. CNS Drugs. 2019;33(12):1167–1186.
   PubMed Web of Science ®Google Scholar
• Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence. Complement Ther Med. 2019;42:65–81.
   PubMed Web of Science ®Google Scholar
• Nedkova-Hristova V, Vélez-Santamaría V, Casasnovas C. Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral Centre. BMC Neurol. 2020;20(1):403.
   PubMed Web of Science ®Google Scholar
• Gruber R, Constantin E, Frappier JY, et al. Training, knowledge, attitudes and practices of canadian health care providers regarding sleep and sleep disorders in children. Paediatr Child Health. 2017;22(6):322–327.
   PubMed Web of Science ®Google Scholar
• Sánchez-López AL, Ortiz GG, Pacheco-Moises FP, et al. Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis. Arch Med Res. 2018;49(6):391–398.
   PubMed Web of Science ®Google Scholar
• Zarezadeh M, Khorshidi M, Emami M, et al. Melatonin supplementation and pro-inflammatory mediators: a systematic review and meta-analysis of clinical trials. Eur J Nutr. 2020;59(5):1803–1813.
   PubMed Web of Science ®Google Scholar
• Mirza-Aghazadeh-Attari M, Reiter RJ, Rikhtegar R, et al. Melatonin: an atypical hormone with major functions in the regulation of angiogenesis. IUBMB Life. 2020;72(8):1560–1584.
   PubMed Web of Science ®Google Scholar
• Scheer FA, van Montfrans GA, Van Someren EJ, et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004;43(2):192–197.
   PubMed Web of Science ®Google Scholar
• Green EA, Black BK, Biaggioni I, et al. Melatonin reduces tachycardia in postural tachycardia syndrome: a randomized, crossover trial. Cardiovasc Ther. 2014;32(3):105–112.
   PubMed Web of Science ®Google Scholar
• Hadi A, Ghaedi E, Moradi S, et al. Effects of melatonin supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Horm Metab Res. 2019;51(03):157–164.
   PubMed Web of Science ®Google Scholar
• James SP, Sack DA, Rosenthal NE, et al. Melatonin administration in insomnia. Neuropsychopharmacology. 1990;3(1):19–23.
   PubMed Web of Science ®Google Scholar
• Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet. 1991;337(8750):1121–1124.
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled- release melatonin. Lancet. 1995;346(8974):541–544.
   PubMed Web of Science ®Google Scholar
• Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18(7):598–603.
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, Zhdanova I. Improvement of sleep quality by melatonin. Lancet. 1995;346(8988):1491–1491.
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr. 1997;24(2):223–231.
   PubMed Web of Science ®Google Scholar
• Dawson D, Rogers NL, Van Den Heuvel CJ, et al. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs. J Biol Rhythms. 1998;13(6):532–538.
   PubMed Web of Science ®Google Scholar
• Kayumov L, Brown G, Jindal R, et al. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med. 2001;63(1):40–48.
   PubMed Web of Science ®Google Scholar
• Almeida Montes LG, Ontiveros Uribe MP, Cortes Sotres J, et al. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci. 2003;28(3):191–196.
   PubMed Web of Science ®Google Scholar
• Mundey K, Benloucif S, Harsanyi K, et al. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep. 2005;28(10):1271–1278.
   PubMed Web of Science ®Google Scholar
• Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24(5):239–249.
   PubMed Web of Science ®Google Scholar
• Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591–596.
   PubMed Web of Science ®Google Scholar
• van Geijlswijk IM, van der Heijden KB, Egberts AC, et al. Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology (Berl). 2010;212(3):379–391.
   PubMed Web of Science ®Google Scholar
• Sletten TL, Magee M, Murray JM, et al. Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: a double-blind, randomised clinical trial. PLoS Med. 2018;15(6):e1002587.
   PubMed Web of Science ®Google Scholar
• Eckerberg B, Lowden A, Nagai R, et al. Melatonin treatment effects on adolescent students’ sleep timing and sleepiness in a placebo-controlled crossover study. Chronobiol Int. 2012;29(9):1239–1248.
   PubMed Web of Science ®Google Scholar
• Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep. 1998;21(1):52–68.
   PubMed Web of Science ®Google Scholar
• Weiss MD, Wasdell MB, Bomben MM, et al. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry. 2006;45(5):512–519.
   PubMed Web of Science ®Google Scholar
• Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44(1):57–64.
   PubMed Web of Science ®Google Scholar
• Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(2):145–150.
   PubMed Web of Science ®Google Scholar
• Cortesi F, Giannotti F, Sebastiani T, et al. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21(6):700–709.
   PubMed Web of Science ®Google Scholar
• Appleton R, Jones A, Gamble C, et al. The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS). Health Technol Assess. 2012;16(40):239.
   Web of Science ®Google Scholar
• Gringras P, Nir T, Breddy J, et al. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948–957.
   PubMed Web of Science ®Google Scholar
• van Maanen A, Meijer AM, Smits MG, et al. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017;40(2):zsw038.
   Web of Science ®Google Scholar
• Asayama K, Yamadera H, Ito T, et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003;70(4):334–341.
   PubMedGoogle Scholar
• Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in alzheimer’s disease. Sleep. 2003;26(7):893–901.
   PubMed Web of Science ®Google Scholar
• Serfaty M, Kennell-Webb S, Warner J, et al. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry. 2002;17(12):1120–1127.
   PubMed Web of Science ®Google Scholar
• Jain SV, Horn PS, Simakajornboon N, et al. Melatonin improves sleep in children with epilepsy: a randomized, double-blind, crossover study. Sleep Med. 2015;16(5):637–644.
   PubMed Web of Science ®Google Scholar
• Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. 2000;61(5):373–377.
   PubMed Web of Science ®Google Scholar
• Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9(1):41–50.
   PubMed Web of Science ®Google Scholar
• Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20(12):1151–1158.
   PubMed Web of Science ®Google Scholar
• Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.
   PubMed Web of Science ®Google Scholar
• Auld F, Maschauer EL, Morrison I, et al. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10–22.
   PubMed Web of Science ®Google Scholar
• Van Geijlswijk IM, Korzilius HPLM, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010;33(12):1605–1614.
   PubMed Web of Science ®Google Scholar
• Wei S, Smits MG, Tang X, et al. Efficacy and safety of melatonin for sleep onset insomnia in children and adolescents: a meta-analysis of randomized controlled trials. Sleep Med. 2020;68:1–8.
   PubMed Web of Science ®Google Scholar
• Braam W, Smits MG, Didden R, et al. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis. Dev Med Child Neurol. 2009;51(5):340–349.
   PubMed Web of Science ®Google Scholar
• Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and Meta-analysis. Arch Dis Child. 2018;103(12):1155–1162.
   PubMed Web of Science ®Google Scholar
• Parker A, Beresford B, Dawson V, et al. Oral melatonin for non-respiratory sleep disturbance in children with neurodisabilities: systematic review and Meta-analyses. Dev Med Child Neurol. 2019;61(8):880–890.
   PubMed Web of Science ®Google Scholar
• Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res. 1996;5(1):61–65.
   PubMed Web of Science ®Google Scholar
• Andrade C, Srihari BS, Reddy KP, et al. Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry. 2001;62(1):41–45.
   PubMed Web of Science ®Google Scholar
• Smits MG, van Stel HF, van der Heijden K, et al. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2003;42(11):1286–1293.
   PubMed Web of Science ®Google Scholar
• Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27(1):87–98.
   PubMed Web of Science ®Google Scholar
• Dodge NN, Wilson GA. Melatonin for treatment of sleep disorders in children with developmental disabilities. J Child Neurol. 2001;16(8):581–584.
   PubMed Web of Science ®Google Scholar
• Coppola G, Iervolino G, Mastrosimone M, et al. Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain Dev. 2004;26(6):373–376.
   PubMed Web of Science ®Google Scholar
• O’Callaghan FJ, Clarke AA, Hancock E, et al. Use of melatonin to treat sleep disorders in tuberous sclerosis. Dev Med Child Neurol. 1999;41(2):123–126.
   PubMed Web of Science ®Google Scholar
• Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32(5):585–589.
   PubMed Web of Science ®Google Scholar
• Braam W, Didden R, Smits M, et al. Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. J Intellect Disabil Res. 2008;52(Pt 3):256–264.
   PubMed Web of Science ®Google Scholar
• Braam W, Didden R, Smits MG, et al. Melatonin for chronic insomnia in angelman syndrome: a randomized placebo-controlled trial. J Child Neurol. 2008;23(6):649–654.
   PubMed Web of Science ®Google Scholar
• Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord. 2011;41(2):175–184.
   PubMed Web of Science ®Google Scholar
• Mohammadi MR, Mostafavi SA, Keshavarz SA, et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iran J Psychiatry. 2012;7(2):87–92.
   PubMedGoogle Scholar